Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Targeted enzyme therapy of experimental glomerulonephritis in rats.
R B White, … , M E Lamm, S N Emancipator
R B White, … , M E Lamm, S N Emancipator
Published May 1, 1991
Citation Information: J Clin Invest. 1991;87(5):1819-1827. https://doi.org/10.1172/JCI115203.
View: Text | PDF
Research Article

Targeted enzyme therapy of experimental glomerulonephritis in rats.

  • Text
  • PDF
Abstract

We sought to determine whether systemic administration of proteases ameliorates membranous nephritis induced in rats by immunization and challenge with cationic bovine gamma globulin, and whether targeting of protease to glomerular capillaries increases efficacy. Proteases substituted with biotin were targeted via the cationic protein avidin A, which by virtue of its charge has affinity for the glomerular basement membrane. Despite identical pretreatment proteinuria, rats given untargeted protease (biotin-conjugated without avidin, or unconjugated plus avidin) had significantly less proteinuria than saline-treated controls and nephrotic rats given avidin plus biotin-conjugated (targeted) protease had even less proteinuria and reduced glomerular rat IgG and C3. Among more severely nephrotic rats, targeted protease was again more effective than untargeted protease at reducing proteinuria, and also decreased the size of electron-dense glomerular deposits, hypercholesterolemia, and creatininemia. Inactivated targeted proteases had no effect on proteinuria, hypercholesterolemia, or azotemia. Finally, active targeted protease did not affect proteinuria in the nonimmune mediated nephrosis induced by puromycin aminonucleoside. We conclude that systemic protease can specifically diminish glomerular immune deposits, proteinuria, hyperlipidemia, and creatininemia associated with experimental immune complex glomerulonephritis but not toxic nephrosis, and that targeted protease is more effective than untargeted protease.

Authors

R B White, L Lowrie, J E Stork, S S Iskandar, M E Lamm, S N Emancipator

×

Total citations by year

Year: 2022 2016 2010 2008 2000 1999 1997 Total
Citations: 1 1 1 1 1 1 1 7
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (7)

Title and authors Publication Year
The Role of Proteases and Serpin Protease Inhibitors in β-Cell Biology and Diabetes.
Kryvalap Y, Czyzyk J
Biomolecules 2022
Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA Nephropathy
L Wang, X Li, H Shen, N Mao, H Wang, L Cui, Y Cheng, J Fan
Scientific Reports 2016
Brief Communication: Immunoglobulin A1 protease: A new therapeutic candidate for immunoglobulin A nephropathy
LS Xie, J Huang, W Qin, JM Fan
Nephrology 2010
Microbial IgA protease removes IgA immune complexes from mouse glomeruli in vivo: potential therapy for IgA nephropathy
ME Lamm, SN Emancipator, JK Robinson, M Yamashita, H Fujioka, J Qiu, AG Plaut
The American Journal of Pathology 2008
Treatment of passively transferred experimental autoimmune myasthenia gravis using papain
K Poulas, T Tsouloufis, SJ Tzartos
Clinical & Experimental Immunology 2000
The effect of oral protease administration in the rat remnant kidney model
K Šebeková, J Dämmrich, Z Krivošíková, A Heidland
Research in Experimental Medicine 1999
Targeting of Drugs to Cell Surface Receptors
B Říhová
Critical Reviews in Biotechnology 1997

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts